文献速递消化道肿瘤放疗放疗物理与技术

调强放疗与三维适形放疗在食管癌根治性治疗中的疗效与急性毒性比较

Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
PubMed 文献 · Radiat Oncol · 2017-08-15

该回顾性研究分析了2000至2012年间接受根治性放化疗的93例非转移性食管癌患者(三维适形放疗49例,调强放疗44例),比较局部控制、生存及急性毒性。结果显示两组3年局部复发率、中位无进展生存及中位总生存均无显著差异,但调强组局部复发率数值更低,可能源于剂量提升。

要点

  • 调强放疗与三维适形放疗相比未观察到生存获益。
  • 调强组局部复发率数值更低,可能与剂量提升有关。
  • 单因素分析中仅累积放疗剂量与更优局部复发率相关。

核心结论

  • 调强放疗与三维适形放疗相比未观察到生存获益。
  • 调强组局部复发率数值更低,可能源于剂量提升。
  • 需要前瞻性数据验证上述结果。

研究设计与样本

  • 回顾性分析2000至2012年间在本机构接受根治性放化疗的93例非转移性食管癌患者。
  • 三维适形放疗组49例,调强放疗组44例;排除放疗剂量<50 Gy者。
  • 采用Kaplan-Meier法评估局部复发率、无进展生存和总生存,Cox比例风险模型进行单因素和多因素分析。

主要发现

  • 中位随访34.7个月。
  • 3年局部复发率三维适形组28.6%,调强组22.7%(p=0.620)。
  • 中位无进展生存分别为13.8个月和16.6个月(p=0.448)。
  • 中位总生存分别为18.4个月和42.0个月(p=0.198)。
  • 单因素分析中仅累积放疗剂量与更优局部复发率相关(HR 0.736;95%CI 0.635-0.916,p=0.004)。

关键数值与推荐

  • 纳入标准:非转移性食管癌、Karnofsky体能状态评分≥70、根治性治疗意图、接受同步放化疗。
  • 排除标准:放疗剂量<50 Gy。

临床怎么用

  • 在根治性放化疗中,调强放疗可作为三维适形放疗的替代技术,但需注意生存获益尚未证实。
  • 累积放疗剂量与局部控制相关,支持剂量提升策略的进一步研究。

局限性

  • 本研究为单中心回顾性分析,样本量有限。
  • 需要前瞻性数据验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Though the vast majority of seminal trials for locally advanced esophageal cancer (EC) utilized three-dimensional conformal radiotherapy (3DCRT), the advanced and highly conformal technology known as intensity-modulated radiotherapy (IMRT) can decrease doses to critical cardiopulmonary organs. To date, there have been no studies comparing both modalities as part of definitive chemoradiation (dCRT) for EC. Herein, we investigated local control and survival and evaluated clinical factors associated with these endpoints between cohorts. METHODS: We retrospectively analyzed 93 patients (3DCRT n = 49, IMRT n = 44) who received dCRT at our institution between 2000 and 2012 with the histologic diagnosis of nonmetastatic EC, a Karnofsky performance status of ≥70, curative treatment intent, and receipt of concomitant CRT. Patients were excluded if receiving <50 Gy. Kaplan-Meier analysis was used to evaluate the endpoints of local relapse rate (LR), progression-free survival (PFS), and overall survival (OS). Cox proportional hazards modeling addressed factors associated with outcomes with univariate and multivariate approaches. Rates of acute toxicities and basic dosimetric parameters were compared between 3DCRT and IMRT patients. RESULTS: Mean follow-up was 34.7 months. The 3-year LR was 28.6% in the 3DCRT group and 22.7% in the IMRT group (p = 0.620). Median PFS were 13.8 and 16.6 months, respectively (p = 0.448). Median OS were 18.4 and 42.0 months, respectively (p = 0.198). On univariate analysis, only cumulative radiation dose was associated with superior LR (hazard ratio (HR) 0.736; 95% confidence interval (CI) 0.635 - 0.916, p = 0.004). Factors clearly affecting survival were not observed. CONCLUSIONS: When comparing 3DCRT- versus IMRT-based dCRT, no survival benefits were observed. However, we found a lower local recurrence rate in the IMRT group potentially owing to dose-escalation. Prospective data are needed to verify the presented results herein.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Haefner MF, Lang K, Verma V, et al. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity. Radiat Oncol. 2017. PMID: 28810885. doi:10.1186/s13014-017-0863-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。